Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Cancer
Solid Tumor
Lymphoma

Interventions

DRUG: Sym021
DRUG: Sym022
DRUG: Sym023

Sponsor

Symphogen A/S